HPP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hudson Pacific Properties Inc (HPP) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown some positive financial trends like revenue growth, the overall financial performance remains weak with negative net income and declining EPS. Additionally, the technical indicators suggest a bearish trend, and the options data reflects bearish sentiment. Analysts' ratings and price target adjustments indicate skepticism about the stock's near-term potential. Given the investor's preference for long-term stability, it is better to hold off on investing in HPP until there is clearer evidence of recovery or stability in the company's fundamentals.
The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 52.528, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest limited upside potential in the near term, with resistance at 6.644 and support at 5.483. Overall, the technical indicators point to a bearish trend.
Hedge funds have significantly increased their buying activity, up 1332.86% over the last quarter. The company has shown revenue growth of 22.11% YoY in Q4 2025, and gross margin has improved significantly.
Net income remains negative at -277.92M, despite improving YoY. EPS has dropped by -46.26% YoY. Analysts have consistently lowered price targets, reflecting skepticism about the company's recovery. Options data indicates bearish sentiment, and the stock's historical trend suggests further downside in the short term.
In Q4 2025, revenue increased by 22.11% YoY to $256.03M, and gross margin improved to 23.63%. However, net income remains negative at -$277.92M, and EPS dropped significantly by -46.26% YoY, indicating ongoing financial struggles.
Analysts have generally lowered their price targets over the past few months. The most recent ratings include a reduction by Goldman Sachs to $7.50 from $12.50 with a Neutral rating, and Cantor Fitzgerald lowering the target to $10 from $13 but maintaining an Overweight rating. Overall, analysts are cautious, with mixed ratings and a focus on the company's challenges in stabilizing its performance.
